Stock profile

Elite Pharmaceuticals, Inc.(ELTP)

Country: United States of AmericaSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: OTC
P/E TTM
22.8
History
P/E NTM
N/A
Market cap
408.22M
Currency USD
KvantraRanki73
Value67
Quality79
Momentum72
Current price
0.36-0.64%
Benchmarks

No price history available.

Key financial summary

Financials in USD
2020202120222023202420252026TTM2027E
Total revenue$m182532345784149N/AN/A
Operating profit$mLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net profit$m-259420-445N/AN/A
EPS reported$LockedLockedLockedLockedLockedLockedLockedLockedLocked
Operating cashflow per share$LockedLockedLockedLockedLockedLockedLockedLockedLocked
Capex per share$LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF per share$LockedLockedLockedLockedLockedLockedLockedLockedLocked
Free cash flow$mLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net debt$mLockedLockedLockedLockedLockedLockedLockedLockedLocked
Book value equity$mLockedLockedLockedLockedLockedLockedLockedLockedLocked
Book value per share$LockedLockedLockedLockedLockedLockedLockedLockedLocked
Number of sharesmLockedLockedLockedLockedLockedLockedLockedLockedLocked
DPS (TTM paid)$LockedLockedLockedLockedLockedLockedLockedLockedLocked

Financial summary

Financials in USD
2020202120222023202420252026TTM2027E
Value
P/E LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
P/B LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
P/S LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
P/FCF LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
EV/EBITDA LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
EV/Sales LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
Earnings Yield LTM%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF Yield%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Quality
ROE%LockedLockedLockedLockedLockedLockedLockedLockedLocked
ROIC%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Operating margin%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Gross margin%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF/Sales%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Growth and momentum
EPS Growth YoY%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Sales Growth YoY%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Net Income Growth YoY%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF Growth%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Operating Profit Growth%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Dividend and capital structure
Dividend Yield%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Dividend Growth%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Payout Ratio%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF/DebtxLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net Debt/EBITDAxLockedLockedLockedLockedLockedLockedLockedLockedLocked
EBIT/Net interestxLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/market cap%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/Equity%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Gross debt/equity%LockedLockedLockedLockedLockedLockedLockedLockedLocked

Price target estimates

Low estimateLocked
High estimateLocked
Price consensusLocked
Last year average price targetLocked
Current price0.36
Return PotentialLocked

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked
Number of covering analystsLocked

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-scoreLockedLockedLocked
Environmental scoreLockedLockedLocked
Social scoreLockedLockedLocked
Governance scoreLockedLockedLocked
Risk ratingLockedLockedLocked

Company overview

Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryUnited States of America
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Elite Pharmaceuticals, Inc. (ELTP)

ELTP · OTC · Healthcare
0.36-0.64%
Sign up to track this stock

No price history available.

KvantraRank73
P/E TTM22.8
P/E NTMN/A
Market cap408.22M
KvantraRank?73 / 100
Value
67
Quality
79
Momentum
72
Financialsin USD
20242025TTM2026
Analyst target
ConsensusLocked
Current0.36
UpsideLocked
LockedLocked
Price consensusLocked
Last year average price targetLocked
Current price0.36
Return PotentialLocked

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-scoreLockedLockedLocked
Environmental scoreLockedLockedLocked
Social scoreLockedLockedLocked
Governance scoreLockedLockedLocked
Risk ratingLockedLockedLocked
About

Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryUnited States of America
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data for this stock

Unlimited access to every company

See plans

Unlock all fundamental data for this stock

Unlimited access to every company

See plans